12:00 AM
 | 
Nov 10, 2008
 |  BC Week In Review  |  Clinical News  |  Regulatory

Norditropin regulatory update

FDA approved an sNDA from Novo Nordisk to expand the label for Norditropin to include treatment of children with short stature born small...

Read the full 91 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >